MedPath

Efficacy comparision of bupivacain vs ropivacain in midpoint transverse process to pleura block in modified radical mastectomy surgeries

Phase 4
Not yet recruiting
Conditions
Malignant neoplasm of breast, , (2) ICD-10 Condition: O||Medical and Surgical,
Registration Number
CTRI/2025/05/087076
Lead Sponsor
Pt JNM Medical College Raipur CG
Brief Summary

This is a randomized Interventional study comparing two drugs I.e. inj. Ropivacaine 0.5% and inj. Bupivacaine 0.25% via midpoint transverse process to pleura block in patients undergoing modified radical mastectomy surgeries in terms of post surgical analgesic efficacy.

Patients will be enrolled with a sample size of 128 ( 64 in each group) , primary outcome will be first rescue analgesia duration using VAS score.  Secondary outcome will be patient satisfaction using Likert score .

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
128
Inclusion Criteria

ASA Grade 1 and 2 patients scheduled for elective MRM surgeries.

Exclusion Criteria

Patient refusal Patient with COPD and lung disease Patient with severe liver disease Obesity with BMI more than 31 Patient on any analgesics Local site infections Local injury Allergic to study drugs.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Post surgical analgesia using VAS score,as first rescue analgesic requirements.Post surgical analgesia using VAS score at 0,2,4,8,10,12,16,20,24 and 48 hours, with Blood pressure, Heart rate, and SpO2 saturation
Secondary Outcome Measures
NameTimeMethod
Patient satisfaction evaluated using, Likert scaleLiberty scale at 0,4,8,12,24 and 48 hours

Trial Locations

Locations (1)

Dr Bhimrao Ambedakar Memorial Hospital ,Raipur Chhattisgarh

🇮🇳

Raipur, CHHATTISGARH, India

Dr Bhimrao Ambedakar Memorial Hospital ,Raipur Chhattisgarh
🇮🇳Raipur, CHHATTISGARH, India
Dr Himanshu Dubey
Principal investigator
9165783431
himanshu20192@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.